Skip to Content

Novavax Inc NVAX

Morningstar Rating
$5.39 +0.45 (9.11%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

NVAX is trading at a 32% discount.
Price
$5.37
Fair Value
$7.00
Uncertainty
Extreme
1-Star Price
$73.99
5-Star Price
$8.68
Economic Moat
Hrqh
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NVAX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$4.94
Day Range
$4.765.50
52-Week Range
$3.5311.36
Bid/Ask
$5.31 / $5.38
Market Cap
$640.28 Mil
Volume/Avg
6,313 / 10.0 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
0.98
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
1,992

Comparables

Valuation

Metric
NVAX
DVAX
MRNA
Price/Earnings (Normalized)
20.5435.38
Price/Book Value
2.662.62
Price/Sales
0.987.075.38
Price/Cash Flow
41.74
Price/Earnings
NVAX
DVAX
MRNA

Financial Strength

Metric
NVAX
DVAX
MRNA
Quick Ratio
0.5312.653.21
Current Ratio
0.7013.813.42
Interest Coverage
−36.67−4.38−113.82
Quick Ratio
NVAX
DVAX
MRNA

Profitability

Metric
NVAX
DVAX
MRNA
Return on Assets (Normalized)
−26.26%3.72%−20.12%
Return on Equity (Normalized)
6.14%−26.85%
Return on Invested Capital (Normalized)
1.92%−26.68%
Return on Assets
NVAX
DVAX
MRNA
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRTsjt$550.4 Bil
VRTX
Vertex Pharmaceuticals IncKfmmntf$111.8 Bil
REGN
Regeneron Pharmaceuticals IncNvkkj$107.9 Bil
MRNA
Moderna IncDpc$36.3 Bil
ARGX
argenx SE ADRWmryl$23.0 Bil
BNTX
BioNTech SE ADRCcl$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncRrpgj$19.2 Bil
BMRN
Biomarin Pharmaceutical IncLknnjn$16.4 Bil
RPRX
Royalty Pharma PLC Class ANnsnxl$13.4 Bil
INCY
Incyte CorpYbfvms$13.3 Bil

Sponsor Center